Drug, across the briefings

Eprenetapopt across 47 cancers

Eprenetapopt appears in 47 of the briefings; no FDA label names any of them.

DiseaseFDA labelOpen Targets stage, on which geneTrialsActive
Acute lymphoblastic leukemiaphase 3 on TP53——
Acute myeloid leukemiaphase 3 on TP5330
Anal cancerphase 3 on TP53——
Basal cell carcinomaphase 3 on TP53——
Bladder cancerphase 3 on TP5310
Breast cancerphase 3 on TP53——
Burkitt lymphomaphase 3 on TP53——
Cervical cancerphase 3 on TP53——
Cholangiocarcinomaphase 3 on TP53——
Chronic lymphocytic leukemiaphase 3 on TP5310
Chronic myeloid leukemiaphase 3 on TP53——
Colorectal cancerphase 3 on TP53——
Cutaneous squamous cell carcinomaphase 3 on TP53——
Diffuse large B-cell lymphomaphase 3 on TP53——
Endometrial cancerphase 3 on TP53——
Esophageal cancerphase 3 on TP5310
Ewing sarcomaphase 3 on TP53——
Gallbladder cancerphase 3 on TP53——
Gastric cancerphase 3 on TP5310
Gastrointestinal stromal tumourphase 3 on TP53——
Glioblastomaphase 3 on TP53——
Head and neck cancerphase 3 on TP53——
Hepatocellular carcinomaphase 3 on TP53——
Lower-grade gliomaphase 3 on TP53——
Lung cancerphase 3 on TP5310
Mantle cell lymphomaphase 3 on TP5320
Marginal zone lymphomaphase 3 on TP53——
Medulloblastomaphase 3 on TP53——
Merkel cell carcinomaphase 3 on TP53——
Mesotheliomaphase 3 on TP53——
Multiple myelomaphase 3 on TP53——
Myelodysplastic syndromesphase 3 on TP5340
Myeloproliferative neoplasmsphase 3 on TP5320
Nasopharyngeal carcinomaphase 3 on TP53——
Osteosarcomaphase 3 on TP53——
Ovarian cancerphase 3 on TP5320
Pancreatic cancerphase 3 on TP53——
Prostate cancerphase 3 on TP5310
Rhabdomyosarcomaphase 3 on TP53——
Small cell lung cancerphase 3 on TP53——
Small intestine cancerphase 3 on TP53——
Soft tissue sarcomaphase 3 on TP53——
Testicular cancerphase 3 on TP53——
Thyroid cancerphase 3 on TP53——
Vulvar cancerphase 3 on TP53——
Waldenström macroglobulinaemiaphase 3 on TP53——
Wilms tumourphase 3 on TP53——

The label column is the briefing's openFDA stage: a label whose Indications and Usage names the disease. The Open Targets column is the furthest clinical stage recorded for the drug against any gene on that briefing's target list, in any indication. Trials are ClinicalTrials.gov interventional studies naming the drug and the disease, from the briefing's trials stage; a dash means the briefing did not search this drug in that disease (it searches the drugs Open Targets lists against its own genes), which is not the same as none. Salt forms, biosimilar suffixes and formulation words are merged by the same rule the briefings use.